GlobeNewswire

Monopar Announces Publication of Phase 2 Study Demonstrating ALXN1840 Significantly Improves Copper Balance in Patients with Wilson Disease
19/05/2026
WILMETTE, Ill., May 19, 2026 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (“Monopar” or the “Company”) (Nasdaq: MNPR), a clinical-stage biopharmaceutical company developing innovative treatments for patients with unmet [...]
Aura Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
19/05/2026
BOSTON, May 19, 2026 (GLOBE NEWSWIRE) -- Aura Biosciences, Inc. (NASDAQ: AURA) (“Aura” or the “Company”), a clinical-stage biotechnology company developing precision therapies for solid tumors designed to preserve organ [...]
Journey Medical Corporation to Participate in A.G.P.’s Annual Virtual Healthcare Conference
19/05/2026
SCOTTSDALE, Ariz., May 19, 2026 (GLOBE NEWSWIRE) -- Journey Medical Corporation (Nasdaq: DERM) (“Journey Medical,” “the Company,” “we” or “our”), a commercial-stage pharmaceutical company focused on developing, selling [...]
Olema Oncology to Participate in Upcoming Investor Conferences
19/05/2026
SAN FRANCISCO, May 19, 2026 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and [...]
Eton Pharmaceuticals Expands Rare Disease Portfolio Through Agreement for U.S. Commercialization Rights to IMPAVIDO® (miltefosine)
19/05/2026
IMPAVIDO ® is the first and only FDA-approved oral therapy for visceral, cutaneous, and mucosal leishmaniasis caused by specific Leishmania species Leishmaniasis is a rare but potentially life-threatening parasitic [...]
Cadrenal Therapeutics to Participate in the Lytham Partners Spring 2026 Investor Conference on May 28, 2026
19/05/2026
PONTE VEDRA, Fla., May 19, 2026 (GLOBE NEWSWIRE) -- Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a late-stage biopharmaceutical company advancing novel therapies for life-threatening immune and thrombotic conditions, [...]
Ozari Health Launches Nationwide Telehealth Platform for Compounded Semaglutide and Tirzepatide Starting at $86 Per Month
19/05/2026
LegitScript-verified platform connects patients with licensed providers for GLP-1 weight loss treatment, with transparent pricing, multiple pharmacy options, and no long-term contracts. New York, NY, May 19, 2026 (GLOBE [...]
RxSight, Inc. to Present at the Stifel 2026 Virtual Ophthalmology Forum
19/05/2026
ALISO VIEJO, Calif., May 19, 2026 (GLOBE NEWSWIRE) -- (NASDAQ: RXST) RxSight, Inc., today announced plans to participate in the upcoming Stifel 2026 Virtual Ophthalmology Forum. Management is scheduled to participate in [...]
Annovis Announces Launch of Proposed Public Offering of Common Stock and Accompanying Warrants
19/05/2026
MALVERN, Pa., May 19, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a Phase 3 clinical-stage biotechnology company developing the investigational oral therapy, buntanetap, for [...]
Alps Group Inc Announces Receipt of Nasdaq Notification Regarding Minimum Bid Price Deficiency
19/05/2026
KUALA LUMPUR, Malaysia, May 19, 2026 (GLOBE NEWSWIRE) -- Alps Group Inc (the “Company” or “Alps Group”), the parent company of Alps Life Sciences Inc. (“Alps Holdco”), a fully integrated biotechnology research and [...]
Resmed Announces Participation in the 46th Annual William Blair Growth Stock Conference
19/05/2026
SAN DIEGO, May 19, 2026 (GLOBE NEWSWIRE) -- Resmed (NYSE: RMD, ASX: RMD) today announced Mick Farrell, chairman and chief executive officer, and Aaron Bloomer, chief financial officer, will attend the 46 th Annual [...]
Suja Life to Report First Quarter 2026 Financial Results on June 9, 2026
19/05/2026
OCEANSIDE, Calif., May 19, 2026 (GLOBE NEWSWIRE) -- Suja Life, Inc. (NASDAQ: SUJA) (“Suja Life” or the “Company”), a leading better-for-you beverage company and maker of Suja Organic , Vive Organic , and Slice Soda , [...]
Iridex Reports First Quarter 2026 Financial Results
19/05/2026
2026 Guidance Affirmed MOUNTAIN VIEW, Calif., May 19, 2026 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and [...]
Artiva Biotherapeutics Announces Multiple AlloNK® Data Presentations at EULAR 2026 Congress, Including Late-Breaking Oral Presentation Highlighting Clinical Efficacy Comparable to Autologous CAR T-Cell Therapy in Rheumatologic Diseases
19/05/2026
Late-breaking oral presentation to highlight AlloNK + rituximab clinical responses comparable to autologous CAR T-cell therapy in 31 patients with rheumatologic diseases, including 71% ACR50 response in refractory [...]
Oorja Bio Unveils Clinical Data for ORJ-001, a First-in-Class Therapeutic Targeting Alveolar Epithelial Type 2 (AEC2) Cells for Treatment of Idiopathic Pulmonary Fibrosis (IPF)
19/05/2026
ORJ-001 achieved therapeutic exposure and was well tolerated in Phase 1 study, supporting company’s plans to initiate Phase 2 clinical trial in IPF patients Data from preclinical studies of ORJ-001 demonstrated durable [...]
Oorja Bio Launches as a Clinical-Stage Company to Develop Groundbreaking Therapies for Idiopathic Pulmonary Fibrosis (IPF) and Other Fibrotic Diseases
19/05/2026
Company announces $30 million Series A financing and founding leadership team with expertise in pulmonary drug innovation and track record advancing novel therapies to patients ORJ-001, set to begin a Phase 2 clinical [...]
Ipsen announces late-breaking data from first head-to-head study comparing Dysport® and Botox® in adults with upper limb spasticity
19/05/2026
Phase IV head-to-head, double-blind trial comparing safety and efficacy met its primary and secondary endpoints The DIRECTION trial results show the safety profile for Dysport ® (abobotulinumtoxinA) was non-inferior to [...]
Ipsen annonce des données « late-breaking » issues de la première étude comparative directe entre Dysport® et Botox® chez des adultes atteints de spasticité du membre supérieur
19/05/2026
Essai de phase IV comparatif direct, en double aveugle, évaluant la tolérance et l’efficacité ayant atteint ses critères principaux et secondaires Les résultats de l’étude DIRECTION montrent que le profil de sécurité de [...]
Radiology Associates of North Texas Announces Analysis Projecting More than $51 Million in No Surprises Act Administrative Costs
19/05/2026
Nation’s largest radiology practice reveals BCBS TX has paid just 2% of binding federal arbitration awards, leaving millions in limbo following recent 5th Circuit ruling Fort Worth, TX, May 19, 2026 (GLOBE NEWSWIRE) -- [...]

Pages

Other news

Test 2

Lorem ipsum

Test 1

Lorem upsum